Fluidigm Corporation (NASDAQ:FLDM) today announced its financial results for the second quarter ended June 30, 2012. Product revenue for the second quarter of 2012 was $12.8 million, an increase of 31% from $9.7 million in the second quarter of 2011. Product margin was 69% in the second quarter of 2012, consistent with the 69% in the second quarter of 2011 and up slightly from the first quarter of this year. Total revenue for the second quarter of 2012 was $12.9 million, an increase of 22% from $10.6 million in the second quarter of 2011. Net loss for the second quarter of 2012 was $4.6 million, compared to a net loss of $7.2 million in the second quarter of 2011 (which included a one-time charge of $3.0 million related to a litigation settlement and intellectual property licensing agreements). Non-GAAP net loss for the second quarter of 2012 was $2.9 million, consistent with the $2.9 million non-GAAP net loss for the second quarter of 2011 (see accompanying table for reconciliation of GAAP and non-GAAP measures). “Growth in single-cell genomics, high-throughput gene expression and production genotyping powered our strong performance during the quarter. Demand was healthy for both instruments and consumables, particularly our BioMark™ HD System and 96.96 Dynamic Array™ chip,” stated Gajus Worthington, Fluidigm President and Chief Executive Officer. As of the end of the second quarter, Fluidigm had 565 systems installed at customer locations. Consumables revenue reached high levels, achieving 79% growth during the quarter, compared to the second quarter of 2011. “With each passing quarter, there are more signs that validate our strategic focus around single-cell genomics. Our products are now enabling researchers to change our understanding of biology in profound ways. We believe the C 1™ Single-Cell AutoPrep System will accelerate this, and in fact our first C 1 users are already performing experiments with the system. We have enjoyed strong demand for participation in our Early Access Program, and this high level of enthusiasm for the C 1 is indicative of the growing excitement among researchers to take science down to the level of the individual cell,” Worthington continued. Financial Highlights and Analysis
- Sales of consumables were strong during the second quarter. As in previous quarters, this was mainly due to high demand for production genotyping chips. Increased sales of gene expression and Access Array™ chips, and assays, also contributed meaningfully to consumables revenue growth.
- Instrument revenue growth was driven by robust demand for analytical platforms (BioMark, BioMark HD, EP1™ and after-market instruments), which grew in excess of 20% compared to the second quarter of 2011.
- Instrument/consumables mix was 54% and 46%, respectively, for the second quarter of 2012, compared to 66% and 34%, respectively, in the second quarter of 2011.
- Geographic revenue as a percent of total product revenue was as follows: United States – 51%; Europe – 22%; Asia-Pacific – 16%; Japan – 8%; and Other – 3%.
- Research and development expense was $4.0 million in the second quarter of 2012, compared to $3.4 million in the second quarter of 2011.
- Selling, general and administrative expense was $9.4 million in the second quarter of 2012, compared to $7.8 million in the second quarter of 2011.
- Cash, cash equivalents and investments at the end of the second quarter of 2012 were $38.9 million, compared to $44.9 million at the beginning of the quarter.
- In June, Fluidigm introduced its new C 1 Single-Cell AutoPrep System to attendees at the International Society for Stem Cell Research (ISSCR) meeting in Yokohama, Japan. The C 1 System, based on Fluidigm’s innovative microfluidic technology, enables a researcher to isolate and process individual cells rapidly and reliably for genomic analysis.
- Analytical systems (BioMark, BioMark HD and EP1) surpassed 400 installed instruments at June 30, 2012.
- Scientists from the Cancer Research UK’s Cambridge Research Institute used Fluidigm’s Access Array technology to tag cancerous DNA fragments floating in a patient’s blood in order to determine how a given tumor was responding to treatment – demonstrating the feasibility of liquid biopsies. The paper, entitled “Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA,” published in Science Translational Medicine magazine, received global interest.
- Fluidigm product revenue in the Asia-Pacific region, especially in China, achieved record levels during the second quarter of 2012, representing 16% of Fluidigm’s product revenue during the second quarter.
Conference Call InformationFluidigm will host a conference call today, August 7, 2012 at 5:30 p.m. Eastern Time. The call can be accessed by calling (877) 556-5248 (domestic toll-free) or (720) 545-0029 (international toll). Fluidigm will also provide a live stream of its second quarter of 2012 financial results conference call for investors at: http://investors.fluidigm.com/events.cfm. The link will not be active until 5:15 p.m. Eastern Time on August 7, 2012. A telephone replay of the teleconference will be available 90 minutes after the end of the call at (855) 859-2056 (domestic toll-free), or (404) 537-3406 (international toll), access code 13399164. The conference call will also be archived on the Fluidigm investor’s page at: http://investors.fluidigm.com. Statement Regarding Use of Non-GAAP Financial Information The Company has presented certain financial information in accordance with GAAP and also on a non-GAAP basis for the second quarter of 2012 and 2011. Management believes that non-GAAP financial measures, taken in conjunction with GAAP financial measures, provide useful information for both management and investors by excluding certain non-cash and other expenses that are not indicative of the Company’s core operating results. Management uses non-GAAP measures to compare the Company’s performance relative to forecasts and strategic plans and to benchmark the Company’s performance externally against competitors. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of the Company’s operating results as reported under U.S. GAAP. The Company encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Reconciliations between GAAP and non-GAAP results are presented in the accompanying table of this release. Use of Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements relating to the launch and impact of new products, market trends, current estimates of 2012 product and grant revenue, our future growth, quarterly growth in our revenue, and our strategy and position in the field of single-cell genomics research. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to, risks relating to market acceptance of our products, our ability to successfully launch new products and applications, competition, our sales, marketing and distribution capabilities, our planned sales and research and development activities, reduction in research and development spending or changes in budget priorities by customers, interruptions or delays in the supply of components or materials for our products, and risk associated with international operations. Information on these and additional risks, uncertainties, and other information affecting Fluidigm’s business and operating results are contained in our Annual Report on Form 10-K for the year ended December 31, 2011 and other filings with the Securities and Exchange Commission. Additional information will also be set forth in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2012 to be filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Fluidigm Corporation disclaims any obligation to update these forward-looking statements.
About FluidigmFluidigm (NASDAQ:FLDM) develops, manufactures and markets microfluidic systems for growth markets in the life science and agricultural biotechnology, or Ag-Bio, industries. Fluidigm’s proprietary microfluidic systems consist of instruments and consumables, including chips, assays and other reagents. These systems are designed to significantly simplify experimental workflow, increase throughput and reduce costs, while providing the excellent data quality demanded by customers. Fluidigm actively markets four microfluidic systems, including eight different commercial chips, to leading academic institutions, diagnostic laboratories, and pharmaceutical, biotechnology and Ag-Bio companies. Fluidigm products are marketed for research purposes only (not for diagnostic use). For more information, please visit www.fluidigm.com. Fluidigm, the Fluidigm logo, BioMark, Dynamic Array, C 1, Access Array and EP1 are trademarks or registered trademarks of Fluidigm Corporation.
|CONDENSED CONSOLIDATED BALANCE SHEETS|
|June 30, 2012||December 31, 2011 (1)|
|Cash and cash equivalents||$||9,854||$||13,553|
|Accounts receivable, net||9,612||9,253|
|Prepaid expenses and other current assets||1,603||1,343|
|Total current assets||55,697||70,033|
|Property and equipment, net||4,024||3,256|
|Other non-current assets||4,210||4,537|
|LIABILITIES AND STOCKHOLDERS' EQUITY|
|Accrued compensation and related benefits||2,088||2,442|
|Other accrued liabilities||2,947||2,787|
|Deferred revenue, current portion||1,733||2,011|
|Long-term debt, current portion||2,828||8,921|
|Line of credit||1,875||-|
|Total current liabilities||14,766||20,171|
|Long-term debt, net of current portion||-||1,217|
|Other non-current liabilities||1,246||1,041|
|Total stockholders' equity||48,920||56,897|
|Total liabilities and stockholders' equity||$||64,932||$||79,326|
|(1) Derived from audited consolidated financial statements.|
|CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS|
|(In thousands, except per share amounts)|
|Three Months Ended June 30,||Six Months Ended June 30,|
|License, collaboration, and grant revenue||180||865||369||1,150|
|Costs and expenses:|
|Cost of product revenue||3,926||2,965||7,472||5,878|
|Research and development||3,987||3,422||8,266||6,642|
|Selling, general and administrative||9,421||7,843||18,824||15,285|
|Total costs and expenses||17,334||17,230||34,562||30,805|
|Loss from operations||(4,386||)||(6,654||)||(10,669||)||(11,532||)|
|Other income (expense), net||9||42||(52||)||(610||)|
|Loss before income taxes||(4,579||)||(7,124||)||(11,230||)||(14,414||)|
|Provision for income taxes||(1||)||(62||)||(40||)||(110||)|
|Deemed dividend related to the change in conversion rate of Series E convertible preferred stock||-||-||-||(9,900||)|
|Net loss attributed to common stockholders||$||(4,580||)||$||(7,186||)||$||(11,270||)||$||(24,424||)|
|Net loss per share attributed to common stockholders, basic and diluted||$||(0.22||)||$||(0.36||)||$||(0.55||)||$||(1.58||)|
|Shares used in computing net loss per share attributed to common stockholders, basic and diluted||20,544||19,975||20,469||15,464|
|CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS|
|Six Months Ended June 30,|
|Depreciation and amortization||688||503|
|Stock-based compensation expense||2,014||1,328|
|Write-off of debt discount upon note repayment||-||1,157|
|Other non-cash items, net||68||840|
|Changes in assets and liabilities, net||(2,143||)||(2,212||)|
|Net cash used in operating activities||(10,643||)||(12,908||)|
|Purchases of investments||(22,365||)||(57,712||)|
|Proceeds from sales and maturities of investments||34,760||3,490|
|Purchases of property and equipment||(1,239||)||(714||)|
|Other investing activities||-||(21||)|
|Net cash provided by (used in) investing activities||11,156||(54,957||)|
|Proceeds from initial public offering, net of issuance costs||-||76,946|
|Proceeds from exercise of stock options||1,306||242|
|Repayment of long-term debt, net||(5,478||)||(1,831||)|
|Repayment of line of credit||-||(3,125||)|
|Net cash (used in) provided by financing activities||(4,172||)||72,232|
|Effect of foreign exchange rate fluctuations on cash and cash equivalents||(40||)||39|
|Net (decrease) increase in cash and cash equivalents||(3,699||)||4,406|
|Cash and cash equivalents at beginning of period||13,553||5,723|
|Cash and cash equivalents at end of period||$||9,854||$||10,129|
|RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION|
|(In thousands, except per share amounts)|
|Three Months Ended June 30,||Six Months Ended June 30,|
|Net loss attributed to common stockholders (GAAP)||$||(4,580||)||$||(7,186||)||$||(11,270||)||$||(24,424||)|
|Deemed dividend related to the change in conversion rate of Series E convertible preferred stock||-||-||-||9,900|
|Stock-based compensation expense||1,079||538||2,014||1,328|
|Depreciation and amortization||377||277||731||625|
|Loss on disposal of property and equipment||-||-||25||-|
|Change in the fair value of convertible preferred stock warrants and related expense, net||-||-||-||718|
|Net loss (Non-GAAP)||$||(2,922||)||$||(2,859||)||$||(7,991||)||$||(6,581||)|
|Shares used in net loss per share calculation - basic and diluted (GAAP and Non-GAAP)||20,544||19,975||20,469||15,464|
|Net loss per share - basic and diluted (GAAP)||$||(0.22||)||$||(0.36||)||$||(0.55||)||$||(1.58||)|
|Net loss per share - basic and diluted (Non-GAAP)||$||(0.14||)||$||(0.14||)||$||(0.39||)||$||(0.43||)|
|(1) The Company reports non-GAAP results which exclude stock-based compensation expense, depreciation of property and equipment, amortization of long-term debt discount, interest expense related to long-term debt, and the write-off of debt discount upon note repayment and remeasurement adjustment for convertible preferred stock warrant fair value, net of gain from extinguishment of convertible preferred stock warrants.|